Global Iron Chelation Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Iron Chelation Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
In a healthy body, when the stores of iron are sufficient, the intestines reduce the absorption of this mineral from food and drink to prevent its levels from rising too high.
People with iron overload disorders absorb more iron than usual from food or supplements. The body cannot excrete the extra iron fast enough, so it continues to build up. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas.
There are several types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops as a result of another disease or condition.
The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
Iron Chelation Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Iron Chelation Drug market is projected to reach US$ 430.7 million in 2034, increasing from US$ 715 million in 2022, with the CAGR of -6.9% during the period of 2024 to 2034. Demand from Transfusional Iron Overload and NTDT Caused Iron Overload are the major drivers for the industry.
Global Iron Chelation Drug key players include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, etc. Global top five manufacturers hold a Revenue Market Share over 35%. Europe accounts for the most Sales Market Share, which have a share over 40%, followed by North America. In terms of product, Deferasirox is the largest segment, with a Revenue Market Share over 90%. And in terms of application, the largest Application is Transfusional Iron Overload, followed by NTDT Caused Iron Overload.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Iron Chelation Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis
Chiesi Group
Sun Pharma
Cipla
Natco Pharma
Taro Pharm
Gland Pharma
Segment by Type
Deferasirox
Deferoxamine
Deferiprone
Transfusional Iron Overload
NTDT Caused Iron Overload
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Iron Chelation Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Iron Chelation Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Iron Chelation Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Iron Chelation Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Iron Chelation Drug introduction, etc. Iron Chelation Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Iron Chelation Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
People with iron overload disorders absorb more iron than usual from food or supplements. The body cannot excrete the extra iron fast enough, so it continues to build up. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas.
There are several types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops as a result of another disease or condition.
The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
Iron Chelation Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Iron Chelation Drug market is projected to reach US$ 430.7 million in 2034, increasing from US$ 715 million in 2022, with the CAGR of -6.9% during the period of 2024 to 2034. Demand from Transfusional Iron Overload and NTDT Caused Iron Overload are the major drivers for the industry.
Global Iron Chelation Drug key players include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, etc. Global top five manufacturers hold a Revenue Market Share over 35%. Europe accounts for the most Sales Market Share, which have a share over 40%, followed by North America. In terms of product, Deferasirox is the largest segment, with a Revenue Market Share over 90%. And in terms of application, the largest Application is Transfusional Iron Overload, followed by NTDT Caused Iron Overload.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Iron Chelation Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis
Chiesi Group
Sun Pharma
Cipla
Natco Pharma
Taro Pharm
Gland Pharma
Segment by Type
Deferasirox
Deferoxamine
Deferiprone
Segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Iron Chelation Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Iron Chelation Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Iron Chelation Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Iron Chelation Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Iron Chelation Drug introduction, etc. Iron Chelation Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Iron Chelation Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices